Innovation1 Biotech Inc. announced the appointment of Frederick E. Pierce, II, to its Board of Directors. Mr. Pierce is a serial biotech entrepreneur with more than 20 years of senior leadership and operating experience in building successful biotech companies. He is the CEO and co-founder of Decoy Therapeutics, a pharmaceutical company that has created a rapid antivirals development platform.

He is also an advisor to the Canadian Consulate of Boston/CambridgeÆs Healthcare and Technology Accelerator. As a board member of the Canadian Entrepreneurs of New England, he serves as Chairman of the Life Sciences Leadership Council. Mr. Pierce also served as a Senior Advisor for Bionest Partners, which provides leading global pharmaceutical and biotech companies strategic advice on matters including market access, licensing valuation and strategy, reimbursement, drug pricing and venture capital diligence support services.

Prior to joining Innovation1, Mr. Pierce was President of SemBioSys Genetics. His multi-faceted career has entailed various roles, including Investor Relations at Javelin Pharmaceuticals where he served as Vice President. He was also Vice President of Business Development and Investor Relations before becoming CEO of GlycoGenesys Inc. He started as Vice President of Finance and Investors Relations for SafeScience, the predecessor company of GlycoGenesys.

Mr. PierceÆs finance career included Lehman Brothers, Kidder Peabody and Merrill Lynch. Mr. Pierce received a B.S. in Chemistry from Hampshire College.